The consistent association between the effects of anti-HER2 therapies and immune infiltration has been reported in breast cancer and supports that an anti-tumor immune response can modulate the effect of anti-HER2 therapy [30,31]. The gene discussed is ERBB2; the disease is breast carcinoma.